BioSpace News Archive

Business

Deerfield-Backed Vicinitas Launches to Target Key Protein Stabilization

Vicinitas launched with a Series A round worth $65 million and was co-led by a16z and Deerfield Management, with participants including Droia Ventures, GV, and the Berkeley Catalyst Fund.

August 1, 2022
·
3 min read
·
Mark Terry
Career Advice

What to Do After You’ve Been Laid Off

Being laid off from a job is stressful. Fortunately, there are steps you can take to curb some of that stress, relieve financial worries and make finding your next position as smooth a process as possible.

August 1, 2022
·
3 min read
·
Franklin Carpenter
Drug Development

Nuvation Down to Last Drug in Pipeline After Dropping Glioma Candidate

The decision comes after the FDA put NUV-422, its candidate for high-grade gliomas, on a partial clinical hold, citing safety concerns.

August 1, 2022
·
2 min read
·
Tristan Manalac
As Psychedelic Therapies Advance, Regulators Must Weigh Results against Safety

BioSpace sat down with Katy Powell, a psychiatric mental health nurse practitioner in Portland, Oregon, to discuss the relative risks and benefits associated with psychedelic-assisted therapy.

August 1, 2022
·
6 min read
·
Gail Dutton
Drug Development

AAIC 2022: Vivoryon, Anavex and More Tout Innovation in Alzheimer’s Space

The ongoing AAIC 2022 in San Diego has delivered positive news for the AD space. We look at updates from Vivoryon, Anavex and Argentinian scientists below.

August 1, 2022
·
5 min read
·
Vanessa Doctor, RN
Business

Ipsen Invests Potential $1.6B to Turbo-Charge Marengo’s Path to the Clinic

Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.

August 1, 2022
·
3 min read
·
Tristan Manalac
Celebrating Recent and Potential Milestones on RNA Appreciation Day

August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the “vital biological molecule.”

August 1, 2022
·
4 min read
·
Mark Terry
Drug Development

Priority Review of Gamida’s Novel Transplant Therapy Reflects Urgency, Efficacy

The FDA granted Priority Review for omidubicel with a target action date of January 30, 2023. Omidubicel is a first-in-class, advanced NAM (nicotinamide)-enabled stem cell therapy.

August 1, 2022
·
3 min read
·
Mark Terry
Business

AstraZeneca Axes Trials with Innate, Moderna

Innate Pharma announced that a planned futility interim analysis of the INTERLINK-1 Phase III trial sponsored by AstraZeneca failed to hit a pre-defined threshold for efficacy.

August 1, 2022
·
4 min read
·
Mark Terry
Automated CPR Devices Market: Rising Prevalence of Different Respiratory Disorders to Drive the Market

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global automated cardiopulmonary resuscitation devices market is expected to witness moderate growth during the forecast period between 2021 and 2031.

August 1, 2022
·
6 min read